SCHEMBL1961003

SCHEMBL1961003

C=CCc1cnc2c(ccn2S(=O)(=O)c2ccccc2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.53
HTR6 P50406 10/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
HPGD P15428 1/20 0.43
TSHR P16473 1/20 0.43
HTT P42858 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.41
PKM P14618 1/20 0.41
HDAC3 O15379 2/20 0.40
HDAC4 P56524 2/20 0.40
HDAC1 Q13547 2/20 0.40
HDAC7 Q8WUI4 2/20 0.40
HDAC2 Q92769 2/20 0.40
HDAC10 Q969S8 2/20 0.40
HDAC11 Q96DB2 2/20 0.40
HDAC8 Q9BY41 2/20 0.40
HDAC6 Q9UBN7 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1959975 0.84 CYP2C19 (0.57) CYP2C19HTR6MEN1KMT2AALDH1A1
SCHEMBL27873188 0.84 CYP2C19 (0.57) CYP2C19HTR6MEN1KMT2AALDH1A1
SCHEMBL1964662 0.84 CYP2C19 (0.57) CYP2C19HTR6MEN1KMT2AALDH1A1
SCHEMBL1962675 0.84 CYP2C19 (0.57) CYP2C19HTR6MEN1KMT2AALDH1A1
SCHEMBL1963791 0.81 CYP2C19 (0.53) CYP2C19HTR6MEN1KMT2AALDH1A1
SCHEMBL2565717 0.80 CYP2C19 (0.58) CYP2C19HTR6MEN1KMT2AALDH1A1
SCHEMBL17103496 0.78 HTR6 (0.50) CYP2C19HTR6MEN1KMT2AALDH1A1
SCHEMBL1961013 0.78 CYP2C19 (0.50) CYP2C19HTR6MEN1KMT2AALDH1A1
SCHEMBL10142546 0.77 CYP2C19 (0.61) CYP2C19HTR6MEN1KMT2AALDH1A1
SCHEMBL299699 0.77 CYP2C19 (0.61) CYP2C19HTR6MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2513103-A1 AZAINDOLE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2012-10-24 EP disclosed
US-8222416-B2 Azaindole glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-07-17 US disclosed
WO-2011073117-A1 AZAINDOLE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2011-06-23 WO disclosed
US-20110144105-A1 AZAINDOLE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2011-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144105-A1 AZAINDOLE GLUCOKINASE ACTIVATORS GCK, GCKR, GALK1 CYP2C19 792/4885HTR6 1441/4885MEN1 2759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.